Drugs / NuCel
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07187362 | Oct 2015 → Aug 2019 | intervertebral disk degenerative disorder, osteoarthritis, spine | Midwest Spine & Brain Institute | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02314416 | May 2015 | — | Augusta University | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02070484 | Feb 2014 → Mar 2017 | lumbar disk degenerative disorder, spinal stenosis, spondylolisthesis, spondylolysis +1 | OhioHealth | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NuCel | “Patients will receive amniotic stem cells(NuCel) embedded in collagen matrix for wound coverage” NCT02314416 ↗2“placental derived allograft stem cells (NuCel, Nutech, Birmingham, Alabama)” NCT07187362 ↗ |
| Modality | Cell therapy | “Stemcell allograft” NCT02070484 ↗ |